Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novo Nordisk and Oxford University to Further Enhance Diabetes Research

Published: Tuesday, November 05, 2013
Last Updated: Tuesday, November 05, 2013
Bookmark and Share
Partnership will establish a number of postdoctoral fellowship opportunities hosted by Oxford University and funded by Novo Nordisk.

Oxford University and Novo Nordisk announce the establishment of an international fellowship programme that aims to support the career and scientific development of young, exceptional research talent within diabetes. 

“We are honoured to establish the International PostDoctoral Fellowship Programme with Oxford University, which has such valuable expertise in the study and treatment of diabetes. By combining our company’s discovery and clinical development strengths with the research expertise and academic tradition of Oxford University, we can support the development of a new generation of exceptional diabetes researchers to eventually drive innovation further and improve the lives of the patients,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk.

As part of the agreement, a total of 12 young leading researchers will be offered a 3-year grant to support their research within the fields of diabetes, metabolism and endocrinology. The goal of the new programme is to support the development of a new generation of research leaders while further developing scientific excellence within diabetes. 

“This new programme will support the best young researchers doing novel work in the understanding of diabetes and its treatment. It is these early career researchers that will produce the new ideas, discoveries and advances that will improve diabetes treatment and care in the future. We’re delighted to partner with Novo Nordisk to provide this level of funding and support which will be important in enabling both their research and their career development,” said Professor Hugh Watkins of the Radcliffe Department of Medicine at Oxford University.

A joint steering committee with members from both Oxford University and Novo Nordisk will oversee the programme and assess research proposals from scientists at both organisations. 

The first four fellows in the programme will start in the autumn of 2014.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novo Nordisk Buys New Hampshire Production Plant
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech.
Thursday, August 28, 2014
Novo Nordisk Expects to Hire 6,000 Employees by 2022
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development.
Wednesday, June 11, 2014
Novo Nordisk Invests $100M in New Danish Purification Pilot Plant
Company increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark.
Monday, March 17, 2014
Novo Nordisk Receive Positive Opinions from the European Regulatory Authorities
The Committee for Medicinal Products for Human Use adopted positive opinions, recommending marketing authorisations, for Tresiba® and Ryzodeg® for the treatment of diabetes mellitus in adults.
Tuesday, October 23, 2012
Top researcher takes over as Director of the Protein Center
Jiri Lukas will join The Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen on 1 April.
Thursday, March 01, 2012
Novo Nordisk Establishes Type 1 Diabetes R&D Center in Seattle
The new center will combine Novo Nordisk's history in diabetes treatment with the company's growing expertise in immunotherapy.
Wednesday, January 25, 2012
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!